icon-folder.gif   Conference Reports for NATAP  
 
  The International Liver Congress™
EASL - European Association for the
Study of the Liver
Paris France
11-15 April 2018
Back grey_arrow_rt.gif
 
 
 
Time to Viral Suppression Does not Impact SVR in Patients
Treated With Glecaprevir/Pibrentasvir for 8 Weeks

 
 
  Reported by Jules Levin
EASL 2018 April 11-15 Paris France
 
Christoph Sarrazin1, Jordan J Feld2, Douglas E Dylla3, Sanjeev Arora4, David Victor III5, Yiran B Hu3, Stanley Wang3, Federico J Mensa3, David Wyles6
1JW Goethe University Hospital, Frankfurt, Germany and St. Josefs-Hospital Wiesbaden, Germany; 2Toronto Centre for Liver Disease, University of Toronto, Toronto, Ontario, Canada; 3AbbVie Inc., North Chicago, Illinois, United States;
4University of New Mexico, Albuquerque, New Mexico, United States; 5Houston Methodist Hospital, Houston, Texas, United States; 6Denver Health Medical Center, Denver, Colorado, United States

0423181

0423182

0423183

0423184

0423185

0423186

0423187

0423188

0423189